

# **Diabetes and Covid-19: risks, management, and learnings from other national disasters**

Running title: Diabetes and COVID-19

Jamie Hartmann-Boyce DPhil<sup>1\*</sup>, Elizabeth Morris MRCGP<sup>2</sup>, Clare Goyder MRCGP<sup>2</sup>, Jade Kinton<sup>3</sup>, James Perring<sup>3</sup>, David Nunan PhD<sup>1</sup>, Kamal Mahtani PhD<sup>1</sup>, John B. Buse PhD<sup>4</sup>, Stefano Del Prato PhD<sup>5</sup>, Linong Ji<sup>6</sup> MD, Ronan Roussel PhD<sup>7</sup>, Kamlesh Khunti PhD<sup>8</sup>

\*corresponding author. Email: Jamie.hartmann-boyce@phc.ox.ac.uk

1 Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

2 Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

3 Medical Sciences Division, University of Oxford, UK

4 University of North Carolina School of Medicine, Chapel Hill, NC USA

5 Department of Clinical & Experimental Medicine, Section of metabolic Diseases and Diabetes, University of Pisa, Pisa, Italy

6 Peking University Diabetes Center, Peking University People's Hospital, China

7 APHP, Federation de Diabetologie, Bichat Hospital, Paris, France; INSERM, UMR\_S 1138, Centre de Recherche des Cordeliers, Paris, France; Université de Paris, UFR de Médecine, Paris, France

8 Diabetes Research Centre, University of Leicester, UK

Word count:

Tables: 3

Figures: 2

## **Abstract**

Evidence relating to the impact of COVID-19 in people with diabetes (PWD) is limited but continuing to emerge. People with diabetes appear to be at increased risk of more severe COVID-19 infection, though evidence quantifying the risk is highly uncertain. The extent to which clinical and demographic factors moderate this relationship is unclear, though signals are emerging that link higher BMI and higher HbA1c to worse outcomes in PWD with COVID-19. As well as posing direct immediate risks to people with diabetes, COVID-19 also risks contributing to worse diabetes outcomes due to disruptions caused by the pandemic, including changes to routine care, stress, diet and physical activity. Countries have used various strategies to support people with diabetes during and following this pandemic. There is a high potential for COVID-19 to exacerbate existing health disparities, and research and practice guidelines need to take this into account. Evidence on the management of long-term conditions during national emergencies suggests various ways to mitigate the risks presented by these events.

## **Introduction**

People with diabetes (PWD) have been identified as being at increased risk of serious illness from COVID-19. COVID-19 also presents substantial indirect risks to PWD through disruptions in healthcare and lifestyle factors. Understanding these risks and best ways to mitigate them in the short- and longer-term is key to facilitating informed decision-making during and after the COVID-19 pandemic.

Evidence relating to COVID-19 and diabetes is limited but continuing to emerge. In this paper we summarise evidence identified through rapid reviews. We consider direct and indirect risks posed to PWD by COVID-19 and management

considerations for PWD both with and without COVID-19 infection. Recognising limitations in evidence related to COVID-19, we also bring together leaders in diabetes care from countries with high rates of COVID-19, highlighting experiences from the most affected countries including Italy, France, China, the UK and US.

## **Diabetes and risks from COVID-19**

### **COVID-19 infection: contracting the disease**

It is unclear if PWD are more likely to contract COVID-19. PWD are considered at increased risk of infection generally, which has been extended to COVID-19(1).

Community testing for COVID-19 remains limited hence data predominantly comes from hospitalised cohorts. Systematic reviews primarily consisting of data from China have estimated rates of 8% (95% CI 6%-11%)(2); 7.87% (95% CI 6.57 to 9.28%)(3); and 9.7% (95% CI 6.9% to 12.5%)(4) of diabetes in people hospitalised with COVID-19. The percentage hospitalisation appears higher in the US where from February 12–March 28, 2020, PWD accounted for 10.9% of all COVID-19 patients (similar to the proportion of the US population with diabetes), 24% of hospitalised cases (non ICU) and 32% of ICU admissions.(5) A recent (preprint) UK study found uncomplicated diabetes to be the second most common co-morbidity (19%) in patients hospitalised with COVID-19; complicated diabetes is reported in a figure only but prevalence looks to be approximately 6.5%.(6)

### **COVID-19 infection: disease severity**

Though issues with study quality and imprecision make it extremely difficult to quantify, current data suggest Covid-19 is associated with worse outcomes in PWD. Reports which aggregate data from multiple centres are summarised in Table 1. There is a notable paucity of data on what moderates the relationship between

diabetes and COVID-19 severity. Increased age, being male, hypertension and cardiovascular co-morbidities are associated with increased risks for COVID-19 severity(7), and are likely to be closely related to diabetes status. It is plausible that, BMI(8), ethnicity(9), type of diabetes, diabetes control, and certain medications(10) all may also play a role. In two cohort studies (France and UK, UK study pre-print) in PWD hospitalised with COVID-19, higher BMI was positively associated with worse COVID-19 outcomes when compared to people with BMI 25-29.9 kg/m<sup>2</sup>.(11) Data on diabetes type and COVID-19 outcomes is only beginning to emerge, but preliminary (not yet peer reviewed) data from England (see Table 1) suggests risks may be higher in people with Type 1 diabetes compared to Type 2 (though risk was increased in all PWD regardless of type).(12) Data on glucose control and COVID-19 outcomes are discussed below.

### **Association between blood glucose control and COVID-19 outcomes**

There is limited data to date on the association between blood glucose control and COVID-19 outcomes. A retrospective study of 451 people with COVID-19 with diabetes and/or hyperglycaemia from the US reported that people uncontrolled hyperglycaemia had longer length of stay and higher mortality compared to people without diabetes or uncontrolled hyperglycemia.(19) Another retrospective study of people with Type 2 diabetes from China reported that well-controlled blood glucose correlated with improved outcomes in infected cases.(20) Worse infection may predispose to more difficulty managing blood glucose, so the causal mechanism behind correlations between glucose control and worse COVID-19 outcomes is unclear.

Two recent UK studies (both pre-print) reported that diabetes was independently associated with a higher risk of death which increased with higher HbA1c.(12, 18) Compared to people without diabetes, one study reported that PWD with HbA1c > 7.5% (58mmol/mol) had a higher chance of in-hospital death than those with HbA1c < 7.5% (<7.5% HR 1.50, 95% CI 1.40 to 1.60; ≥ 7.5% HR 2.36 (2.18 to 2.56)).(18) In a separate analysis, PWD with HbA1c > 10% (86 mmol/mol) had a higher risk of in-hospital death related to COVID-19 than those with an HbA1c of 6.5 to 7% (48-53 mmol/mol) (HbA1c >10% compared to HbA1c 6.5 to 7% adjusted HR 2.19 (95% CI 1.46 to 3.29) for Type 1; 1.62 (95% CI 1.48 to 1.79) Type 2).(12) These data suggest that diabetes control pre-infection has a role to play in COVID-19 outcomes. In contrast, a French observational study in PWD hospitalised with COVID-19 did not find an association between long-term glucose control and COVID-19 outcomes, but had a smaller sample.(11)

### **Indirect risks to PWD posed by COVID-19**

Healthcare services, and in some cases access to medication and supplies, have been disrupted by COVID-19. Evidence from other national emergencies show that such disruptions can lead to worse diabetes outcomes during and after these events.(21-23) Diet and physical activity are mainstays of diabetes self-management and can reduce risk of worse outcomes in PWD and those with cardiometabolic multimorbidities.(24) Though yet to be addressed by the Covid-19 literature, the pandemic presents significant disruption to both: a US survey of PWD found more than a third of respondents reported their diet is now less healthy, and half report exercising less.(25) The current pandemic and social isolation are likely to increase rates of anxiety and depression which may also lead to poor adherence of medications and worsening of risk factor control.(26; 27)

## **Managing diabetes during the COVID-19 pandemic**

### **Reducing risk from COVID-19**

There is little evidence on how PWD can reduce their risk during the COVID-19 pandemic beyond following general infection control guidance within each country. More frequent blood glucose monitoring (in people who self-monitor) and has been suggested, though it is unclear what evidence was used to make these recommendations.(1)

### **Considerations for diabetes management in all PWD**

Figure 1 summarises specific considerations for diabetes management during national emergencies.

#### *Self-management*

There is little information on the effectiveness of self-management/self-education during the pandemic. A variety of online services have been implemented, but have yet to be assessed (see individual commentaries). The wider literature on care of long-term conditions during national emergencies suggests a role for educational materials.(28) Evidence for interventions aiming to optimise self-management in PWD which are potentially feasible in disaster contexts include: mobile phone app(29); web or computer based(30); text-message(31; 32); and self-monitoring of blood glucose.(33; 34) The latter two show the most promise based on the available literature. However, the interventions tested may not be widely available or may require healthcare resources to be set up. In addition, choice of format programmes should be tailored to patient preferences which will vary by age and sociodemographic groups.(35)

### *Diabetes services*

Guidelines for routine diabetes care during the COVID-19 pandemic vary by country. Themes are summarised in Table 2. Studies of remote consultations have generally found positive results, though their generalisability to the current pandemic may be limited.(36) Within diabetes, there is little evidence to support or oppose remote support.(37; 38)

### *Mental health and diabetes-related distress*

There are overarching concerns about the impact of the Covid-19 pandemic on mental health and wellbeing.(43; 44) PWD are more prone to mental health issues than the general population.(45) Adherence to treatment can worsen when people are distressed or have depression(26), as seen both during and after disasters.(46; 47) We found no evidence directly pertaining to management of diabetes-related anxiety or distress during this pandemic. In the general literature, there is mixed evidence on interventions to reduce diabetes-related distress, and the vast majority of interventions tested involve face-to-face contact; an unsuitable format in the current context.(48)

## **Managing COVID-19 in PWD**

Management of PWD with COVID-19 generally follows standard sick-day rules. Considerations that may be specific to COVID-19 are summarised below.

### *Medication*

Most COVID-19 related consensus statements recommend stopping metformin and SGLT2 inhibitors during acute illness and following the sick day rules. DPP4 inhibitors, GLP1 receptor agonists and insulin are the preferred options in particular for hospitalised patients (see Figure 2).(49; 50) There has been some discussion

regarding use of ACE inhibitors and angiotensin receptor blockers (ARBs) being associated with worse outcomes in COVID-19, particularly in PWD. However, in view of data showing potential benefits, the current recommendation is to continue with these therapies.(49)

A number of studies are currently testing chloroquine/hydroxychloroquine for prevention or management of COVID-19. Careful glucose monitoring will be required in people with diabetes due to their antidiabetic properties, with the potential risk of hypoglycaemia which is associated with increased risk of cardiac arrhythmia, cardiovascular events and mortality.(51)

### *Management in hospital*

Guidance emphasises the importance of referring to local specialist diabetes teams and of managing hyperglycaemia.(52) A narrative review suggests insulin is the preferred agent for control of hyperglycemia in this context.(1) In the US, a major early focus for hospital management was to move inpatient care for PWD to 'virtual' formats where possible, to reduce the need for personal protective equipment (PPE). This included: use of electronic health records to interrogate data; telephone communication between diabetes care providers and inpatients and hospital staff; expanded "diabetes self-management protocols" allowing selected inpatients to monitor their own glucose and self-administer insulin with oversight and advice from the virtual care team; and, in some institutions, initiating inpatient continuous glucose monitoring and/or flash systems. To minimize the need for ICU beds, several institutions launched subcutaneous insulin protocols for the treatment of diabetic ketoacidosis on floors with adequate nursing staffing. Virtual diabetes care teams focused on supporting transitions to lower levels of care or outpatient settings.



## **Experiences from countries with high rates of COVID-19**

We summarise here experiences from five countries which have had significant COVID-19 outbreaks.

### **China**

During the outbreak in China, many PWD were unable to access healthcare providers (HCP) or medical supplies due to stay-at-home orders or quarantine. Hospitals reduced the number of appointments drastically. To mitigate the impact of those changes on diabetes management, several organizations issued guidance to PWD on how to cope with the situation.(53; 54) The guidance developed by the Chinese Geriatric Endocrine Society mainly focussed on prevention and early discovery of hyperglycaemic crises and management of medications, and provided detailed instructions on how to get access to certified internet-based medical services through smart phones.(54) If PWD urgently needed to see a HCP in hospital, detailed guidance on how to prepare for consultations before leaving home and minimize exposure to virus were given en route and during the hospital visit. Guidance was promoted in the form of reading material and lectures given by medical professionals through internet-based public media such as Baidu Health (an equivalent of Google in China) and the WeChat mobile app. An expert recommendation on insulin treatment of hyperglycaemia in patients affected with COVID-19 was developed.(55)

### **France**

On 12th March, President Macron ordered most people to stay at home, especially "at risk" groups, including PWD. Many PWD were struck by the announcement and were not expecting to be publicly identified as such, without answers to basic questions. On 18th March, a group of HCPs and researchers from the Federation of

Diabetology, launched a web-app, CoviDIAB, to provide PWD with diabetes-specific, scientifically-based information and to provide support. This free service includes access to a frequently updated media library and to live webinars with nurses, physicians, and experts. Twice a week, registrants also receive short questionnaires about Covid-19 symptoms and tests for anxiety/depression. If indicated, registrants automatically receive a notice suggesting medical contact, and phone calls may follow. At the time of writing, tens of thousands of patients were registered. Empathy was a driving principle in design, and comments suggest that the service helps people to understand and self-manage their individual risk, and to limit disruption in lifestyle and care. An evaluation will indicate to what extent it reduces the burden of disease. Recommendations have been formulated by the French-speaking Diabetes Society to promote the intensification of glycaemic control by remote support by professionals and frequent self-monitoring. However, extremely limited evidence was available to guide both patients and HCPs. In response, a group of physicians and researchers from 50 French hospitals designed and launched a large register to collect data on PWD hospitalised with COVID-19 and their prognosis (CORONADO, NCT04324736). Recruitment has exceeded expectation; short-term results should be released soon.

## **Italy**

The first cases COVID-19 in Italy were recorded early in February. Tragically, Italy has suffered amongst the highest number of deaths in the world.<sup>(56)</sup> At the time of writing this, the death rate in Italy was estimated at 122.52 per 1000 infections, i.e. a 10-fold higher rate than Germany (14.14 per 1000 infections).<sup>(57)</sup> This could be due to demographic features of the Italian population, which include a large proportion (23%) of people aged  $\geq 65$ .<sup>(58)</sup> From March 9th, social confinement rules were issued

including access to out-patient clinics. Access to diabetes clinics has been limited to urgent cases and remote contacts via telephone or video teleconsultation have been officially approved and reimbursed by the National Health System. Prescriptions of glucose-lowering agents requiring specialist approval (DPP4i, SGLT2i, GLP1RAs, and new basal insulin analogues) were automatically renewed until the end of May. Special joint recommendations have been promptly issued by the Italian Society of Diabetes (SID), the Association of Italian Diabetologists (AMD), the Italian Society of Endocrinology (SIE) and the Italian Society of Pediatric Endocrinology (SIEDP).(59) The same organizations have opened a Facebook page entitled “One hour with AMD, SID and SIEDP” allowing PWD and their relatives to contact specialists.(60) A government webpage providing simple and pragmatic recommendations has been created focusing on disruptions to physical activity and diet as a result of social confinement.(61) Discussions are currently ongoing regarding restarting clinical activities and how to organize post-COVID diabetes clinics.

## **UK**

Over 90% of PWD in the UK are managed in primary care, by enhanced diabetes-skilled primary care physicians, nurses and healthcare assistants. These models have shown to be effective in reducing hospitalisations, outpatient attendance and admissions for diabetes-related complications.(62) In March, the government issued guidance on social distancing and self-isolation.(63) In England, people considered especially clinically vulnerable (including some but not all PWD) were contacted by the government with advice on shielding. All people at high risk, including PWD, have been advised to only leave the house for limited periods for essential shopping and one form of exercise.(64) The Primary Care Diabetes Society and the Association of British Clinical Diabetologists have issued guidance on managing

people with diabetes in primary care.(65) The national charity Diabetes UK has been active in giving advice to PWD through their website and social media. Both primary and secondary care are providing both emergency and routine follow-ups using telephone or video consultations including support for mental wellbeing, though there are some regional variation. Social media channels have been set up where HCPs are sharing experience in managing people in the community and hospital and exchanging new guidance. A number of self-management education programmes have been made freely available. There are also discussions regarding longer-term plans to phase in face-to-face consultations for routine chronic disease management.

## **US**

The lack of universal health coverage poses additional challenges to PWD and their care providers during the COVID-19 pandemic in the US. There has been an almost wholesale switch to virtual care for outpatient appointments, but many failings in this approach. Phone visits provide a much lower rate of reimbursement than a video visits but many of the most vulnerable patients have inadequate equipment or connectivity to support video visits. Contacts with certified diabetes educators by phone or video are not reimbursed. Additional efforts have been made to communicate with PWD at home to ensure that they are safe. Laboratory and physical exam monitoring of complications has virtually ceased for most patients as long as they symptomatically remain well. Many patients have lost insurance coverage. Prescription fills for diabetes medications are down 10%; a survey of PWD found one in six respondents needing insulin experienced a problem. A similar proportion reported issues with obtaining test strips, and a quarter of respondents reported issues with obtaining pump or CGM supplies.(25) Many pharmaceutical

companies have stepped in to increase access to otherwise unaffordable medications. In data available through the end of March, relatively early in the US COVID-19 course, approximately 80% of clinicians reported serious strain and nearly two-thirds were uncertain whether they would be able to keep their practices open due to insufficient financial resources and low volume of reimbursable work. Overall visits (virtual and face-to-face) for chronic asymptomatic care were down ~50%.<sup>(66)</sup> As the future course of the epidemic in the US is uncertain and seems likely to persist for many weeks, the threat to PWD is grave. The hope is that new government initiatives and innovation on the part of stakeholders will fill the emerging cracks in an already fragmented system.

### **Considerations for management of long-term conditions during national emergencies**

Evidence on the management of long-term conditions during national emergencies suggests various ways to mitigate the risks presented by these events, which predominantly fall under two phases: planning and response.<sup>(28)</sup> These are outlined in Table 3.

### **After COVID-19**

There is much uncertainty as to how the COVID-19 pandemic will end and what will be left in its wake. Disruptions that arise due to national emergencies can lead to increased HbA1c in those affected up to 16 months later, with some evidence that this is particularly the case for people of lower socioeconomic status and those treated with insulin.<sup>(23; 28)</sup> A lack of access to routine healthcare is a leading cause of morbidity and mortality after disasters; stroke, acute myocardial infarctions, and diabetes complications are all shown to increase after the immediate threat has

dissipated.(21; 67) Services such as diabetes clinics may also rethink their organisation to minimise risk of ongoing transmission.

## **Discussion**

The need for decisive action creates an important tension when evidence is limited. An example here is the classification of PWD as being at increased risk from COVID-19, and therefore subject to increased preventative measures. Though risk is clearly increased, quantification is scant. There is little to no evidence on potentially moderating factors, despite the fact that these data are routinely collected in datasets used for existing analyses; the results presented are often unadjusted and use single disease categories, ignoring potential differences between type 1 and type 2 diabetes and multimorbidities, which are associated with worse outcomes.(68)

In the face of a limited evidence base relating directly to COVID-19, decisions can be informed by international experiences to date and, to some extent, from the literature as it relates to other national emergencies. This latter source of evidence shows the toll of disruptions to diabetes care is often most pronounced *after* the acute phase of the emergency or disaster has passed. In some cases, the excess morbidity and mortality in the aftermath of national emergencies is higher than the toll during the emergency itself. History issues a stark warning here when considering the balance between diverting resources towards the acute COVID-19 crisis, and maintaining routine care for people living with long-term conditions.

Finally, in reviewing what has been written on the topic of diabetes and COVID-19, we have been struck by two noticeable absences. The first is the absence of literature on wider contextual factors. PWD are likely to be impacted by COVID-19 just as much outside the healthcare setting as within it, with particular concerns

relating to disruptions to diet and physical activity, increased stress, and burdens on mental health and wellbeing, yet the literature to date focusses almost exclusively on clinical management. The other unspoken issue in the literature we reviewed is that of inequality. COVID-19 is not an equal-opportunities disease. The burden will disproportionately be borne by people from less-advantaged groups.(69) Emerging data also suggests that COVID-19 may pose more of a risk to non-white ethnic groups.(9) Diabetes discriminates in similar ways, and the intersection of diabetes and COVID-19 creates a maelstrom in which existing health disparities risk exacerbation with profound and long-lasting consequences. COVID-19 holds a mirror to our health care systems and care of PWD; may we do all we can now to make that reflection favourable in hindsight.

### **Acknowledgements**

The submitted work had no funding. Parts of this article are based on Rapid Reviews conducted for the Centre for Evidence-Based Medicine's COVID-19 Evidence Service.(28; 70; 71)

### **Contributions from authors**

KM, KK, DN, JHB, EM and CG were involved in concept and design. JHB, EM, CG, JK, and JP reviewed studies for inclusion and extracted relevant data. JBB, SDP, LJ, RR, and KK contributed experiences from individual countries. JHB drafted the remainder of the article. All authors edited and approved the final manuscript.

### **Funding statement**

This work was not funded; therefore, funders had no role in the writing of the manuscript or decision to submit it for publication. The corresponding author had full access to all data and final responsibility for the decision to submit for publication.

KK acknowledges support from the National Institute for Health Research Applied Research Collaboration East Midland (NIHR ARC-EM) and the NIHR Leicester Biomedical Research Centre. JBB: Supported by grants from the National Institutes of Health, Bethesda, MD USA (UL1TR002489, P30DK124723). EM is funded by a Wellcome Trust fellowship. The views expressed are those of the authors and not those of the Universities, the NIHR or the Department of Health and Social Care.

### **Declarations of interest**

Dr. Buse reports non-financial support and other from Adocia, AstraZeneca, Dance Biopharm, Dexcom, Eli Lilly, Fractyl, GI Dynamics, Intarcia Therapeutics, Lexicon, MannKind, Metavention, NovaTarg, Novo Nordisk, Orexigen, PhaseBio, Sanofi, Senseonics, vTv Therapeutics, and Zafgen, grants and non-financial support from AstraZeneca, Eli Lilly, Intarcia Therapeutics, Johnson & Johnson, Lexicon, Medtronic, NovaTarg, Novo Nordisk, Sanofi, Theracos, Tolerion and vTv Therapeutics, personal fees from Cirius Therapeutics Inc, CSL Behring, personal fees and other from Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health, and , grants from National Institutes of Health (UL1TR002489, R01HL110380, U01DK098246, UC4DK108612, U54DK118612, R01DK119913, R01DK112939, R61HL142680, P30DK124723), JDRFI, PCORI and American Diabetes Association, outside the submitted work. Dr. Khunti has received grants from Boehringer Ingelheim, grants from AstraZeneca, grants from Novartis, grants from Novo Nordisk, grants from Sanofi-Aventis, grants from Lilly, grants from Merck Sharp & Dohme, grants from Servier, outside the submitted work. KK has served as a consultant, speaker or an advisory board member for Astrazeneca, Bayer, NAPP, Lilly, Merck Sharp and Dohme, Novartis, Novo Nordisk, Roche, Berlin-Chemie AG/Menarini Group, Sanofi-Aventis, Servier and Boehringer Ingelheim.



Dr. Roussel reports grants, personal fees and non-financial support from Sanofi, personal fees and non-financial support from MSD, personal fees from Astra-Zeneca, grants and personal fees from Novo Nordisk, personal fees from Janssen, personal fees from Eli Lilly, personal fees from Abbott, personal fees from Medtronic, grants and personal fees from Diabnext, personal fees from Mundipharma, outside the submitted work. All other authors have nothing to disclose.

## **References**

1. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2020;14:211-212.
2. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *International Journal of Infectious Diseases* 2020;doi: <https://doi.org/10.1016/j.ijid.2020.03.017> (pre-print accessed April 2020).
3. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Archives of Academic Emergency Medicine* 2020;8:e35.
4. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology* 2020.
5. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. *MMWR Morbidity and mortality weekly report* 2020;69:382-386.
6. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* 2020:2020.2004.2023.20076042
7. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. *BMJ* 2020;368:m1198.
8. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. *Nature reviews Endocrinology* 2020:1-2.
9. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? *BMJ* 2020;369:m1548.
10. Aronson JK, Ferner RE. ACE inhibitors and angiotensin receptor blockers (ARBs) in Covid-19. <https://www.cebm.net/covid-19/angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/> 2020.
11. Cariou B, Samy H, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia* 2020 (in press).

12. Type 1 and Type 2 diabetes and COVID-19 related mortality in England. NHS England, 20 May 2020 (<https://www.england.nhs.uk/publication/type-1-and-type-2-diabetes-and-covid-19-related-mortality-in-england/>; Accessed 21.5.2020).
13. Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv 2020:2020.2003.2025.20043133.
14. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of Endocrinological Investigation, 2020 (epub ahead of print).
15. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-1242.
16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020;395:1054-1062.
17. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. European Respiratory Journal 2020:2000547.
18. Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020:2020.2005.2006.20092999.
19. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. Journal of Diabetes Science and Technology 2020:1932296820924469.
20. Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 Diabetes. Cell Metabolism 2020.
21. Saulnier DD, Brolin Ribacke K, von Schreeb J. No calm after the storm: A systematic review of human health following flood and storm disasters. Prehospital and Disaster Medicine 2017;32:568-579.
22. Fonseca VA, Smith H, Kuhadiya N, Leger SM, Yau CL, Reynolds K, et al. Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Diabetes Care 2009;32:1632-1638.

23. Ng J, Atkin SL, Rigby AS, Walton C, Kilpatrick ES. The effect of extensive flooding in Hull on the glycaemic control of patients with diabetes. *Diabetic Medicine* 2011;28:519-524.
  
24. Chudasama YV, Zaccardi F, Gillies CL, Dhalwani NN, Yates T, Rowlands AV, Davies MJ, Khunti K. Leisure-time physical activity and life expectancy in people with cardiometabolic multimorbidity and depression. *Journal of Internal Medicine* 2020;287:87-99.
  
25. Impact of COVID-19 on the Diabetes Community in the United States [article online], 2020. Available from [https://d-qa.com/impact-of-covid-19-on-the-usa-diabetes-community/?utm\\_source=Closer+Look+Subscribers+2018&utm\\_campaign=4285f7ac19-2020-04-19\\_WIR\\_4%2F13-4%2F1704\\_18\\_2020&utm\\_medium=email&utm\\_term=0\\_c55d924bf1-4285f7ac19-409220105](https://d-qa.com/impact-of-covid-19-on-the-usa-diabetes-community/?utm_source=Closer+Look+Subscribers+2018&utm_campaign=4285f7ac19-2020-04-19_WIR_4%2F13-4%2F1704_18_2020&utm_medium=email&utm_term=0_c55d924bf1-4285f7ac19-409220105). Accessed 24 April 2020
  
26. Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. *Journal of General Internal Medicine* 2011;26:1175-1182
  
27. Qiu J, Shen B, Zhao M, Wang Z, Xie B, Xu Y. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. *General Psychiatry* 2020;33:e100213
  
28. Hartmann-Boyce J, Mahtani KR. CEBM: Supporting people with long-term conditions (LTCs) during national emergencies. <https://www.cebm.net/covid-19/supporting-people-with-long-term-conditions-ltcs-during-national-emergencies/> (accessed April 18, 2020) 2020
  
29. Aminuddin HB, Jiao N, Jiang Y, Hong J, Wang W. Effectiveness of smartphone-based self-management interventions on self-efficacy, self-care activities, health-related quality of life and clinical outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. *International Journal of Nursing Studies* 2019;103:286
  
30. Pal K, Eastwood SV, Michie S, Farmer AJ, Barnard ML, Peacock R, Wood B, Inniss JD, Murray E. Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* 2013;
  
31. Huang L, Yan Z, Huang H. The effect of short message service intervention on glycemic control in diabetes: a systematic review and meta-analysis. *Postgraduate Medicine* 2019;131:566-571

32. Sahin C, Courtney KL, Naylor PJ, E Rhodes R. Tailored mobile text messaging interventions targeting type 2 diabetes self-management: A systematic review and a meta-analysis. *Digit Health* 2019;5:2055207619845279-2055207619845279
33. Xu Y, Tan DHY, Lee JY-C. Evaluating the impact of self-monitoring of blood glucose frequencies on glucose control in patients with type 2 diabetes who do not use insulin: A systematic review and meta-analysis. *International Journal of Clinical Practice* 2019;73:e13357
34. Malanda UL, Welschen LMC, Riphagen, II, Dekker JM, Nijpels G, Bot SDM. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. *Cochrane Database of Systematic Reviews* 2012;
35. Woolley AK, Chudasama Y, Seidu SI, Gillies C, Schreder S, Davies MJ, Khunti K. Influence of sociodemographic characteristics on the preferred format of health education delivery in individuals with type 2 diabetes mellitus and or cardiovascular disease: a questionnaire study. *Diabetic medicine* 2020 (epub ahead of print).
36. The Health Foundation, "Using virtual consultations in the fight against COVID-19: Interview with Professor Trish Greenhalgh". <https://www.health.org.uk/news-and-comment/newsletter-features/using-virtual-consultations-in-the-fight-against-covid-19> (accessed April 18, 2020) 2020.
37. Farrell K, Holmes–Walker DJ. Mobile phone support is associated with reduced ketoacidosis in young adults. *Diabetic Medicine* 2011;28:1001-1004
38. Viana LV, Gomes MB, Zajdenverg L, Pavin EJ, Azevedo MJ. Interventions to improve patients' compliance with therapies aimed at lowering glycated hemoglobin (HbA1c) in type 1 diabetes: systematic review and meta-analyses of randomized controlled clinical trials of psychological, telecare, and educational interventions. *Trials* 2016;17:94
39. NHS, Royal College of Physicians, and Association of British Clinical Diabetologists: Clinical guide for the management of people with diabetes during the coronavirus pandemic (19th March 2020 Version 2). <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/speciality-guide-diabetes-19-march-v2-updatedpdf> (accessed April 18, 2020) 2020.
40. NHS London Clinical Networks: Outpatient appointment prioritisation for specialist diabetes departments during the coronavirus pandemic. <https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/4-Covid-19-Diabetes-Outpatient-Appointment-Prioritisation-Crib-Sheet-27032020pdf> (accessed April 18, 2020) 2020.
41. NHS London Clinical Networks: Clinical strategy for service management of diabetic foot units during the COVID-19 pandemic.

<https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/5-Covid-19-Clinical-Strategy-for-MDFTs-Crib-Sheet-02042020pdf> (accessed April 18, 2020) 2020.

42. Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P, Looker HC, Ferguson B. Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. *Diabetes Care* 2015;38:488-494

43. World Health Organisation: Mental Health and psychosocial considerations during the COVID-19 outbreak. 18th March 2020. <https://www.who.int/docs/default-source/coronaviruse/mental-health-considerationspdf> (accessed April 18, 2020) 2020.

44. Shelvin, M, McBride O, Murphy J, Miller JG, Hartman TK, et al. Anxiety, depression, traumatic stress, and COVID-19 related anxiety in the UK general population during the COVID-19 pandemic. *PsyArXiv* (preprint) 2020.

45. The All-Party Parliamentary Group for Diabetes (APPG Diabetes): Diabetes and Mental Health. <https://www.diabetes.org.uk/resources-s3/2018-08/Diabetes%20and%20Mental%20Health%20%28PDF%2C%2057MB%29pdf> (accessed April 18, 2020) 2018.

46. Krousel-Wood MA, Islam T, Muntner P, Stanley E, Phillips A, Webber LS, et al. Medication adherence in older clinic patients with hypertension after Hurricane Katrina: Implications for clinical practice and disaster management. *The American Journal of the Medical Sciences* 2008;336:99-104

47. Khan Y, Albache N, Almasri I, Gabbay RA. The management of diabetes in conflict settings: Focus on the Syrian crisis. *Diabetes Spectrum* 2019;32:264-269

48. Chew BH, Vos RC, Metzendorf MI, Scholten R, Rutten G. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* 2017.

49. Ceriello A, Standl E, Catrinou D, Itzhak B, Lalic NM, Rahelic D, et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. *Diabetes Care* 2020 (epub ahead of print).

50. Bornstein D, Rubino F, Khunti K, Mingrone G, Hopkins D, Bireknfeld A, et al. Practical recommendations for the management of diabetes in patients with COVID-19. *Lancet Diabetes & Endocrinology* 2020 (epub ahead of print).

51. Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: A systematic review on

preclinical and clinical trial studies. Journal of Diabetes Research 2020;2020:5214751.

52. NHS London Clinical Networks: Management of diabetes in emergency department during coronavirus pandemic. <https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/Covid-19-Management-of-diabetes-in-emergency-department-crib-sheet-updated-150420.pdf> (accessed April 18, 2020) 2020.

53. Weiqing W, Zhongyan S, Guang W, et al. Expert recommendations for diabetes management in primary care during COVID-19 pandemic. Chin J Endocrinol Metab 2020;36:185-190

54. Linong J, Guangwei L, Qihong G, et al. Guidance on diabetes management in elderly during COVID-19 pandemic. Chin J Diabetes 2020;28:1-6

55. Linong J, Jiajun Z, Zhiguang Z, al. e. Recommendation on insulin treatment in diabetes patients affected with COVID-19. Chin J Diabetes 2020;28:1-5

56. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet (London, England) 2020;395:1225-1228

57. Coronavirus in Europe: Latest numbers on COVID-19 cases and deaths [article online], 2020. Available from <https://www.euronews.com/2020/04/04/covid-19-coronavirus-breakdown-of-deaths-and-infections-worldwide>.

58. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020.

59. Emergenza COVID | SIE - Società Italiana di Endocrinologia [article online], 2020. Available from <http://societaitalianadiendocrinologia.it/html/cnt/emergenza-covid.asp>. Accessed 5 April 2020

60. One hour with AMD, SID and SIEDP [article online], 2020. Available from <http://www.siditalia.it/progetto-un-ora-con-amd-sid-siedp>. Accessed 5 April 2020

61. Nuovo coronavirus in Italia [article online], 2020. Available from <http://www.salute.gov.it/nuovocoronavirus>.

62. Seidu S, Davies MJ, Farooqi A, Khunti K. Integrated primary care: is this the solution to the diabetes epidemic? Diabetic Medicine 2017;34:748-750

63. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19 [article online], 2020. Available from <https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting->

extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19.

64. People at higher risk from coronavirus [article online], 2020. Available from <https://www.nhs.uk/conditions/coronavirus-covid-19/advice-for-people-at-high-risk/>. Accessed 24 April 2020

65. COVID-19 (Coronavirus) Information for Healthcare Professionals [article online], 2020. Available from <https://abcd.care/coronavirus>. Accessed 24 April 2020

66. Available from [https://www.iqvia.com/-/media/iqvia/pdfs/files/iqvia-covid-19-market-tracking-us.pdf?\\_=1587334105503](https://www.iqvia.com/-/media/iqvia/pdfs/files/iqvia-covid-19-market-tracking-us.pdf?_=1587334105503). Accessed 19 April 2020

67. Mokdad AH, Mensah GA, Posner SF, Reed E, Simoes EJ, Engelgau MM. When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters. *Preventing Chronic Disease* 2005;2 Spec no:A04.

68. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of multimorbidity in middle-aged and older adults: An analysis of the UK biobank data. *Mayo Clinic Proceedings* 2018;93:857-866.

69. Royal College of Physicians: "COVID-19 and mitigating impact on health inequalities". <https://www.rcplondon.ac.uk/news/covid-19-and-mitigating-impact-health-inequalities> (accessed April 18, 2020)

70. Hartmann-Boyce J, Morris E, Goyder C, Kinton J, Perring J, Nunan D, Khunti K. CEBM: Diabetes and risks from COVID-19. <https://www.cebm.net/covid-19/diabetes-and-risks-from-covid-19/> (accessed April 18, 2020) 2020

71. Hartmann-Boyce J, Morris E, Goyder C, Kinton J, Perring J, Nunan D, Khunti K. CEBM: Managing diabetes during the COVID-19 pandemic. <https://www.cebm.net/covid-19/managing-diabetes-during-the-covid-19-pandemic/> (accessed April 18, 2020) 2020



## Tables

Table 1. Aggregated data (across studies or centres) on COVID-19 severity in PWD\*

Study design	Country	N studies	N participants	Outcome measure	Risk estimate
Systematic review and meta-analysis(2)**	Multiple	8	3076	Risk of diabetes in severe patients compared to non-severe patients	OR 2.07, 95% CI 0.89 to 4.82
Systematic review and meta-analysis(13)**	Multiple	9	2103	Risk of diabetes in severe patients compared to non-severe patients	OR 2.67, 95% CI 1.91 to 3.7
Systematic review and meta-analysis(4)	Multiple	6	1527	Risk of diabetes in severe/ICU patients compared to non-severe (non-ICU) patients	RR 2.21, 95% CI 0.88 to 5.57
Meta-analysis(14)	China	12	2018	Diabetes rate ratio among patients with more severe versus those with less severe infection	Rate ratio 2.26, 95% CI 1.47 to 3.49
Centre for Disease Control and Prevention report(15)	China	n/a	72,314	Case fatality rate	7.3% in PWD (compared to 2.3% overall)
Center for Disease Control report (5)	USA	n/a	74,439	Not hospitalised	PWD = 6% of all COVID-19 cases
				Hospitalised, not in ICU	PWD = 24% of all COVID-19 cases
				Admitted to ICU	PWD = 32% of all COVID-19 cases
Multi-centre cohort study(16)	China	n/a	191	Risk of in-hospital death in PWD compared to those without (unadjusted)	OR 2.85, 95% CI 1.35 to 6.05
Retrospective review(17)	China	n/a	1590	Likelihood of reaching composite endpoint (admission to ICU, intensive ventilation, or death) in PWD compared to those without (age and smoking status adjusted)	HR 1.59, 95% CI 1.03 to 2.45
Retrospective cohort study(18)**	UK	n/a	17,425,445 (5,683 deaths attributed to COVID-19)	Risk of in hospital death in PWD compared to those without (age, sex and comorbidities adjusted)	HbA1c < 7.5% (58mmol/mol); HR 1.50, 95% CI 1.40 to 1.60. HbA1c ≥ 7.5% (58mmol/mol); 2.36 (2.18 to 2.56)
Population cohort study(12)**	UK	n/a	61,414,470 (23,804 COVID-19)	Risk of in-hospital death in PWD compared to those	Type 1 diabetes OR 3.50 (95% CI 3.15 to 3.89);

			related deaths)	without (adjusted for age, sex, deprivation, ethnicity, geographical region)	Type 2 diabetes OR 2.03 (95% CI 1.97 to 2.09)
--	--	--	-----------------	--	--

\*Definition of severe disease was often not clear; we report here what was reported in the primary literature. Many of the systematic reviews include overlapping studies and have issues with quality and reporting. OR: Odds ratio; RR: risk ratio; HR: hazard ratio

\*\*Pre-print – methods and data have not been subject to peer-review

**Table 2. Selection of guidance and recommendations relating to routine care in PWD during COVID-19 pandemic**

Service	Recommendations
Inpatient diabetes services	<ul style="list-style-type: none"> <li>inpatient diabetes services will need to continue and potentially increase capacity, with need for team approach re: glycaemic control and nutritional status, and consideration of “virtual visits” for reviews (see ‘Management in hospital’)(39)</li> </ul>
Urgent/acute diabetes care (outpatient)	<ul style="list-style-type: none"> <li>face-to-face consultations should continue in the following circumstances: a new diagnosis of T1DM; urgent insulin start where symptomatic, HbA1c &gt; 10% (86 mmol/mol), or ketones detected; teaching blood glucose monitoring for urgent reasons; or in cases where physical examination is essential (e.g. foot ulcer, infection, some points in pregnancy).(40)</li> </ul>
Urgent/acute diabetes care (outpatient)	<ul style="list-style-type: none"> <li>Virtual (telephone, video or email) consultations should be used in the following circumstances: follow-up of new T1 diagnoses; vulnerable patients (recent hospital admission, recurrent severe hypoglycaemia, HbA1c &gt; 11% (99 mmol/mol); intensive follow-up in high risk situations; or where risk of attending an appointment face-to-face is greater than the benefits.(40)*</li> </ul>
Routine diabetes care	<ul style="list-style-type: none"> <li>consider routine diabetes care delivered virtually in the context of broader long-term condition management and prioritisation, taking into account individual risk factors and clinical needs(39)</li> </ul>
Routine diabetes care	<ul style="list-style-type: none"> <li>the following should be deferred: routine appointments where diabetes is stable and well-managed; face-to-face structured group education courses; flash glucose monitoring start sessions; where the risk of attending an appointment is greater than the benefits; and where deferring appointments will not compromise clinical care.(40)</li> </ul>
Foot services for PWD	<ul style="list-style-type: none"> <li>may need to continue at full capacity with consideration of moving support to remote forms where possible(39); many of these services are essential(41)</li> </ul>
Foot services for PWD	<ul style="list-style-type: none"> <li>access to in-person support should continue for those with acute or limb threatening problems(41) or where physical examination is essential(40)</li> </ul>
Foot services for PWD	<ul style="list-style-type: none"> <li>all new referrals should ideally be reviewed within 24 hours (41)</li> </ul>
Pregnancy services for PWD	<ul style="list-style-type: none"> <li>may need to continue at full capacity with consideration of moving support to remote forms where possible(39)</li> </ul>
Pregnancy services for PWD	<ul style="list-style-type: none"> <li>In-person support will be essential for physical examinations and/or teaching blood glucose monitoring at some points in pregnancy(40)</li> </ul>
Blood tests for PWD	<ul style="list-style-type: none"> <li>Urgent blood test monitoring should continue (e.g. declining renal function, raised potassium, low sodium)(40)</li> </ul>
Eye screening for PWD	<ul style="list-style-type: none"> <li>This was not mentioned in the guidance reviewed but we understand in most affected countries eye screening has been halted in view of high risk of transfer. Of note, evidence indicates that risk stratifying is possible.(42)</li> </ul>

\*Note: PWD may be concerned about the need to visit hospital; they should be encouraged to contact

their physician in case of any signs or symptoms related to acute diabetes complications

**Table 3. Strategies suggested for mitigating risks to management of long-term conditions during national emergencies(28)**

<b>Phase</b>	<b>Suggested strategy</b>
Planning	<ul style="list-style-type: none"> <li>• Collaboration, including the role of community-based partnerships</li> </ul>
Planning	<ul style="list-style-type: none"> <li>• Development of culturally adapted resources for people living with long term conditions (LTCs), including print and web-based educational materials and access to support telephone lines</li> </ul>
Planning	<ul style="list-style-type: none"> <li>• Access to online self-management education programmes</li> </ul>
Planning	<ul style="list-style-type: none"> <li>• Monitoring for patients using prescription data on assessing adherence to medications</li> </ul>
Planning	<ul style="list-style-type: none"> <li>• Proactive remote review of patients requiring care for LTCs and their possible needs if healthcare services are disrupted</li> </ul>
Planning	<ul style="list-style-type: none"> <li>• Clear point of contact for patient care should disasters/emergencies occur</li> </ul>
Planning	<ul style="list-style-type: none"> <li>• Improving identification and tracking mechanisms for people living with LTCs</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Triage and resource allocation</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Transfer of care to allied health care professionals including nurses and pharmacists</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Communication between different agencies</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Business continuity plans for pharmacies, and consideration of 30-day supplies from pharmacists</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Ensuring access to appropriate foods where supplies may be limited (for people with LTCs impacted by diet)</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Dedicated patient transportation or mobile clinics for patients requiring in-person care who may be affected by transport difficulties</li> </ul>
Response	<ul style="list-style-type: none"> <li>• Continued guidance from patient support groups</li> </ul>